Genentech

Our Promise is our north star for ourselves, patients, and society. It builds upon our history of forging life-altering scientific breakthroughs and reminds us that we are on a bolder quest than ever before - to be courageous changemakers in solving the world’s most complex health challenges and improving the lives of all patients. http://spr.ly/6049V62k7

Our very own Aviv Regev, head of Genentech Research & Early Development, was recognized by the San Francisco Business Times as one of the Most Influential Women in Bay Area Business! This prestigious honor reflects her remarkable contributions to our company and the broader Bay Area healthcare community. Congrats, Aviv! Learn how her team is using computational approaches for drug discovery to address some of the world’s toughest health problems. https://lnkd.in/g8xUSh79

While multiple sclerosis (MS) is widely known, gaps in diagnosis and treatment remain. That’s why we’re connecting with the MS community to learn and facilitate a new era of understanding of the condition.

Breast cancer, which affects millions of people around the world, continues to drive the need for new, innovative medicines. This mission motivates our team every day to challenge what’s possible and bring forward the next chapter in care. Hear from our very own employees as they share what working in breast cancer means to them, and why they’re passionate about making a difference in the lives of patients. #BreastCancerAwarenessMonth

The FDA has approved our targeted treatment regimen for people with PIK3CA-mutated, advanced HR+/HER2- #breastcancer. PIK3CA is one of the most commonly mutated genes in #metastaticbreastcancer, impacting approximately 40% of people with HR+ breast cancer, and can be detected through biomarker testing. This new regimen offers a new option for patients who have faced a poor prognosis and treatment challenges. Learn more: http://spr.ly/6044U010a

In the U.S., Black and African American individuals are significantly underrepresented among doctors (5.2%) compared to their percentage in the general population (13.6%). Research shows that when the medical workforce accurately reflects the diversity of the patients it serves, health outcomes improve. That’s why we’re proud to support The 15 White Coats' Funding the Future Physicians Initiative, which provides MCAT prep, financial aid and mentorship to underrepresented students pursuing medical degrees. Learn more about the purpose and impact of The 15 White Coats in Stanford Social Innovation Review’s latest issue: http://spr.ly/6044ULn3Q

In a recent study published in Nature Biotechnology, our scientists developed PerturbView, a novel image-based molecular profiling technology that enhances the ability to link genetic changes to phenotypes. Previously scientists could only perform this type of screening in cancer cells, measuring a few variables at a time, but with PerturbView, scientists can screen in a multi-plex manner, analyzing multiple variables simultaneously within a single experiment, and extend its application to diverse systems, including primary cells and tissues. This advancement expands the possibilities for studying cellular behaviors and opens new avenues and applications for image-based molecular profiling. Learn about their work: http://spr.ly/6041UUmfV

We're working to create more equitable health outcomes through inclusive research in #MultipleSclerosis (MS). Hear from our fellow experts and partners, including Dr. Samantha Roman and Laura Julian as they share more about the evolving approach to tackling the healthcare system’s most pressing challenge. http://spr.ly/6040UU5yQ

Congratulations to our Chief Diversity Officer, Quita Beeler Highsmith, MBA, for being named one of Endpoints News’ 2024 Women in Biopharma! Read the full report to learn more about her trailblazing work to advance inclusive research for historically underrepresented communities, and how these efforts are driving meaningful change for patients. http://spr.ly/6048Uo42K

Congratulations to our employees and Roche colleagues whose work to advance women's health has been recognized by the Healthcare Businesswomen's Association with the 2024 ACE Aspire Award. Together, we're addressing gaps in women's health from discovery to care delivery in conditions that predominantly and uniquely impact women, such as breast cancer and multiple sclerosis, and providing comprehensive employee benefits that support every stage of a woman's life--from family planning and pregnancy through menopause. By fostering a more inclusive and equitable healthcare landscape, we can help more women access the care they deserve. #HBAimpact #HBAAC24